Immunology of hematopoietic stem cell transplantation: A brief review of its history

Immunological Reviews

Volumn 157, Issue , 1997, Pages 5-12

  Dupont, Bo ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; METHOTREXATE;

ALLOGENIC BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; COMBINED IMMUNODEFICIENCY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HLA MATCHING; HUMAN; IMMUNOGENETICS; IMMUNOTHERAPY; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; WISKOTT ALDRICH SYNDROME;

ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTORY, 20TH CENTURY; HUMANS; TRANSPLANTATION IMMUNOLOGY;

EID: 0030879221     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1997.tb00970.x     Document Type: Review

References (66)

1. Fabricius-Møller J. Experimental studies of the hemorrhagic diathesis from x-ray sickness. Copenhagen: Levin and Munksgaard; 1922.
2. Jacobson LO, Marks EK, Robson MJ, Gaston E, Zirkle RE. The effect of spleen protection on mortality following x-irradiation. J Lab Clin Med 1949;34:1538-1543.
3. Forman SJ, Blume KG, Thomas ED, eds. Bone marrow transplantation. Boston: Blackwell Scientific Publications; 1994.
4. Lorenz E, Upholf D, Reid TR, Shelton E. Modification of irradiation injury on mice and guinea pigs by bone marrow injections. J Natl Cancer Inst 1951;12:197-201.
5. Trentin JJ. Mortality and skin transplantability in x-irradiated mice receiving isologous or heterologous bone marrow. Proc Soc Exp Biol Med 1956;92:688-693.
6. Ford CE, Hamerton JL, Barnes DWH, Loutit JF. Cytological identification of radiation-chimaeras. Nature 1956;177:452-454.
7. Nowell PC, Cole LJ, Habermeyer JG, Roan PL. Growth and continued function of rat marrow cells in x-radiated mice. Cancer Res 1956;16:258-261.
8. Mathe G, Amiel JL, Schwarzenberg L, Catton A, Schneider M. Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res 1965;25:1525-1531.
9. Thomas ED, Collins JA, Herman EC Jr, Ferrebee JW Marrow transplants in lethally irradiated dogs given methotrexate. Blood 1962;19:217-228.
10. Epstein RB, Bryant J, Thomas ED. Cytogenetic demonstration of permanent tolerance in adult outbred dogs. Transplantation 1967;5:267-272.
11. Gatti RA, Meeuwissen HJ, Allen HD, Hong R, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968;2:1366-1369.
12. Bach FH, et al. Bone marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 1968;2:1364-1366.
13. Santos GW, et al. Marrow transplantation in man following cyclophosphamide. Transplant Proc 1971;3:400-404.
14. Thomas ED, et al. Aplastic anaemia treated by marrow transplantation. Lancet 1972;1:284-289.
15. Graw RG Jr, et al. Bone marrow transplantation from HL-A-matched donors to patients with acute leukemia. Toxicity and antileukemic effect. Transplantation 1972;14:79-90.
16. Buckner CD, et al. Marrow transplantation for the treatment of acute leukemia using HL-A-identical siblings. Transplant Proc 1974;6:365-366.
17. Copenhagen Study Group of Immunodeficiencies. Bone-marrow transplantation from an HL-A non-identical but mixed-lymphocyte-culture identical donor. Lancet 1973;2:1146-1150.
18. O'Reilly RJ, et al. Reconstitution in severe combined immunodeficiency by transplantation of marrow from an unrelated donor. N Engl J Med 1977;297:1311-1318.
19. Horowitz SD, Bach FH, Groshong T, Hong R. Treatment of severe combined immunodeficiency with bone marrow from an unrelated, mixed-leucocyte-culture-nonreactive donor. Lancet 1975;2:431-433.
20. Speck B, Zwaan FE, van Rood JJ, Emisse JG. Allogeneic bone marrow transplantation in a patient with aplastic anemia using a phenotypically HLA-A identical unrelated donor. Transplantation 1973;16:24-28.
21. Lohrmann HP, et al. Bone marrow transplants for aplastic anemia from a HLA and MLC-identical unrelated donor. Blut 1975;31:347-354.
22. Gordon-Smith ED, et al. Bone marrow transplantation for severe aplastic anemia using histocompatible unrelated volunteer donors. Br Med J 1982;225:835-837.
23. Duquesnoy RJ, Zeevi A, Marrari M, Hackbart S, Camitta B. Bone marrow transplantation for severe aplastic anemia using a phenotypically HLA-identical, SB-compatible unrelated donor. Transplantation 1983;35:566-571.
24. Foroozonfar N, et al. Bone marrow transplant from an unrelated donor for chronic granulomatous disease. Lancet 1977;1:210-213.
25. Hansen JA, Clift RA, Thomas ED, Buckner CD, Storb R, Giblett ER. Transplantation of marrow from an unrelated donor to a patient with acute leukemia. N Engl J Med 1980;303:565-567.
26. Storb R, Weiden PL, Graham TC, Lerner KG, Thomas ED. Marrow grafts between DLA-identical and homozygous unrelated dogs. Evidence for an additional locus involved in graft-versus-host disease. Transplantation 1977;24:165-174.
27. Rodt H, Thierfelder S, Eulitz M. Anti-lymphocyte antibodies and marrow transplantation. III. Effect of heterologous anti-brain antibodies in acute secondary disease in mice. J Immunol 1974;4:25-29.
28. Kolb HJ, et al. Anti-lymphocyte antibodies and bone marrow transplantation. VI. Graft versus host tolerance in DLA-incompatible dogs following in vitro treatment of bone marrow with absorbed anti-thymocyte globulin. Transplantation 1979;27:242-245.
29. Vallera DA, Soderling CCR, Carlson GJ, Kersey JH. Bone marrow transplantation across major histocompatibility barriers in mice. Effects of elimination of T cells from donor grafts by pretreatment or antibody alone. Transplantation 1981;31:218-222.
30. Reisner Y, Itsicovitch L, Meshorer A, Sharon N. Hematopoietic stem cell transplantation using mouse bone marrow and spleen cells fractionated by lectins. Proc Natl Acad Sci USA 1978;75:2933-2936.
31. Reisner Y, et al. Transplantation for acute leukemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 1981;2:327-331.
32. Reisner Y, et al. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 1983;61:341-348.
33. Patterson J, et al. Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation. Br J Haematol 1986;63:221-230.
34. Martin PJ, et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 1985;66:664-672.
35. O'Reilly RJ, et al. Transplantation of marrow depleted of T cells by soybean lectin agglutination and E rosette depletion;major histocompatibility complex-related graft resistance in leukemic transplant recipients. Transplant Proc 1985;17:455-459.
36. Goldman JM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Ann Intern Med 1988;108:806-814.
37. Lucas KG, Small TN, Heller G, Dupont B, O'Reilly RJ. The development of cellular immunity to Epstein-Barr Virus following allogeneic bone marrow transplantation. Blood 1996;87:2594-2603.
38. Beatty PG, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985;313:765-771.
39. McCullough J, et al. Bone marrow transplantation from unrelated volunteer donors: summary of conference on scientific, ethical, legal, financial, and other practical issues. Transfusion 1982;12:78-81.
40. James DCO. Organization of a hospital bone marrow panel. In: Smit Sibinga CTh, Das PC, Opelz G, eds. Transplantation and blood transfusion. Boston: Martinus Nijoff; 1984.p.131-139.
41. McElligott MC, Menitove JE, Aster RJ. Recruitment of unrelated persons as bone marrow donors. Transfusion 1986;26:309-314.
42. McCullough J, et al. Development and operation of a program to obtain volunteer bone marrow donors unrelated to the patient. Transfusion 1986;26:315-323.
43. Beatty PG, Atcher C, Hess E, Meyer DM, Slichter SJ. Recruiting blood donors into a local bone marrow donor registry. Transfusion 1989;29:778-782.
44. McCullough J, Scott EP, Halagan N. Effectiveness of a regional bone marrow donor program. JAMA 1988;259:3286-3289.
45. Oudshoorn M, Leeuwen A, Zanden HGMv, Rood JJv. Bone marrow donors worldwide: a successful exercise in international cooperation. Bone Marrow Transplant 1994;14:3-8.
46. Hansen JA. Development of registries of HLA-typed volunteer marrow donors. Tissue Antigens 1996;47:460-463.
47. Storb R, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989;73:1729-1734.
48. Atkinson K, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990;75:2459-2464.
49. Dupont B. Human immunogenetics and histocompatibility testing, 1996. Tissue Antigens 1996;47:457-459.
50. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 1995;13:545-586.
51. Barnes D, Loutit J, Neal F. Treatment of murine leukemia with X-rays and homologous bone marrow. Br Med J 1956;2:626-630.
52. Barnes D, Loutit J. Treatment of murine leukemia with X-rays and homologous bone marrow. Br J Haematol 1957;3:241-252.
53. Bortin M, Rimm A, Saltzstein E. Graft versus leukemia: quantification of adoptive immunotherapy in murine leukemia. Science 1973;179:811-813.
54. Butturini A, Bortin M, Gale R. Graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transplant 1987;2:233-142.
55. Ringdén O, Horowitz M. Graft-versus-leukemia reactions in humans. Transplant Proc 1989;21:2989-2992.
56. Goldman JM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988;108:806-814.
57. Apperley J, et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br J Haematol 1988;69:239-245.
58. Martin P, et al. HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration. Blood 1988;72:1978-1984.
59. Kolb HJ, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-2465.
60. Drobyski WR, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993;82:2310-2318.
61. Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994;330:100-106.
62. Mackinnon S, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995;4:1261-1268.
63. Papadopoulos EB, et al. Infusions of donor leukocytes as treatment of Epstein-Barr virus associated lymphoproliferative disorders complicating allogeneic marrow transplantation. New Engl J Med 1994;330:1185-1191.
64. Rooney CM, et al. Use of gene-modified virus-specific T-lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995;345:9-13.
65. Parham P. NK cells, MHC class I antigens and missing self. Immunol Rev 1997;155:5-221.
66. Thomas L. Introduction: Bone Marrow Transplantation Conference, November 10, 1975. In: Dupont B. Good RA, eds. Immunobiology of bone marrow transplantation. Transplant Proc 1976;8:xv-xvi.